The price of TG Therapeutics Inc (NASDAQ:TGTX) shares last traded on Wall Street rose 12.91% to $34.90.
TGTX stock price is now 42.99% away from the 50-day moving average and 82.18% away from the 200-day moving average. The market capitalization of the company currently stands at $5.43B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $50, TD Cowen recently initiated with Buy rating for TG Therapeutics Inc (NASDAQ: TGTX). On August 02, 2023, Goldman Upgraded its previous ‘Sell’ rating to ‘Neutral’ on the stock reducing its target price from $16 to quote $12, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Lonial Sagar, Director sold 5,000 shares of the company’s stock on Nov 11 ’24. The stock was sold for $152,200 at an average price of $30.44. Upon completion of the transaction, the Director now directly owns 100,195 shares in the company, valued at $3.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11 ’24, Director Charney Laurence N sold 25,000 shares of the business’s stock. A total of $754,875 was realized by selling the stock at an average price of $30.20. This leaves the insider owning 212,479 shares of the company worth $7.42 million. A total of 10.87% of the company’s stock is owned by insiders.
During the past 12 months, TG Therapeutics Inc has had a low of $9.81 and a high of $32.48. As of last week, the company has a debt-to-equity ratio of 1.32, a current ratio of 4.59, and a quick ratio of 3.91. The fifty day moving average price for TGTX is $24.4067 and a two-hundred day moving average price translates $19.1574 for the stock.
The latest earnings results from TG Therapeutics Inc (NASDAQ: TGTX) was released for 2024-09-30. The net profit margin was -5.42% and return on equity was -8.05% for TGTX. The company reported revenue of $83.88 million for the quarter, compared to $165.81 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -49.41 percent.
